NCT03832361View on ClinicalTrials.gov

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2028

Conditions

Endometrial Cancer

Interventions

DRUG

IMGN853

IMGN853 6 mg/kg intravenously every 3 weeks until disease progression

Trial Locations (1)

06510

RECRUITING

Smilow Cancer Hospital at Yale New Haven, New Haven

Sponsors

Collaborators (1)

ImmunoGen, Inc.

All Listed Sponsors

collaborator

ImmunoGen, Inc.

INDUSTRY

lead

Alessandro Santin

OTHER